GlassScriptPhysician profile
Juliet G Appiah
NPI 1992939599
$1,988.59
in general payments reported to CMS, 2019-2025
29 companies · $21.46 in 2025
The $21.46 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,374 · 2020: $273 · 2021: $31.91 · 2022: $64.24 · 2023: $126 · 2024: $98.32 · 2025: $21.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $161 · Education: $84.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $160.95 |
| Education | $84.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $298.93 | 2019-2025 | Keytruda |
| Genentech USA, INC. | $225.05 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $199.64 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $189.61 | 2019-2020 | |
| Pfizer INC. | $141.95 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $123.58 | 2019-2023 | Enhertu |
| Janssen Biotech, INC. | $114.28 | 2019-2023 | |
| Aveo Pharmaceuticals, INC. | $84.50 | 2024 | |
| Amgen INC. | $76.23 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.32 | 2019 | |
| Abbvie INC. | $47.10 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $45.71 | 2019 | |
| Genzyme Corporation | $40.66 | 2019 | |
| Celgene Corporation | $40.29 | 2019-2023 | Pomalyst |
| Bayer Healthcare Pharmaceuticals INC. | $33.49 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $31.73 | 2020 | |
| Tesaro, INC. | $31.62 | 2019 | |
| Array Biopharma INC | $29.52 | 2019 | |
| Exelixis INC. | $25.96 | 2019 | |
| Lilly USA, LLC | $25.75 | 2019-2020 | |
| Daiichi Sankyo INC. | $18.41 | 2019 | |
| Clovis Oncology, INC. | $16.74 | 2019 | |
| Boston Scientific Corporation | $15.12 | 2021 | |
| Taiho Oncology, INC. | $14.50 | 2019 | |
| Dendreon Pharmaceuticals LLC | $13.63 | 2019 | |
| Kite Pharma, INC. | $13.25 | 2020 | |
| Blueprint Medicines Corporation | $13.14 | 2022 | |
| Tersera Therapeutics LLC | $12.28 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juliet Appiah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.